Dhan Chand/LinkedIn
Nov 9, 2024, 10:50
Dhan Chand: Excited to share our latest research at SITC2024
Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn:
“Excited to share our latest research at SITC2024!
Priya Iyer presents AGEN1721, a novel Fc-enhanced bifunctional antibody targeting FAP and TGFβ. AGEN1721 depletes FAP+ CAFs and neutralizes TGFβ to remodel the tumor stroma and promote T cells infiltration and activation in immune excluded tumors.
Check it out at Poster 1355 today!”
Dhan Chand, Ph.D., is Vice President of Research at Agenus, focusing on cancer immunology, immunotherapy, and cell and molecular biology. Previously, he served as a Graduate Research Assistant and Project Co-Leader in the Department of Cell and Systems Biology at the University of Toronto.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 03:14
Apr 18, 2025, 03:06
Apr 18, 2025, 02:16
Apr 18, 2025, 01:21